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INTRODUCTION
Idiopathic sudden sensorineural hearing loss (SSNHL) is defined
as a decline in hearing over 3 days or less and this affects three
or more frequencies by 30 dB or greater without an identifiable
etiology, and it may vary from mild to profound hearing impair-
ment. Steroids appear to be the only efficacious treatment in
controlled clinical trials (1). Systemic steroids produce significant
hearing improvement for patients with moderate to severe SSNHL
(2), while the patients with profound SSNHL have a poor prog-
nosis regardless of the treatment (3, 4).
Intratympanic dexamethasone (ITD) produces significantly
higher perilymph concentrations of steroids than does intravenous
or oral administration (5, 6). Although its efficacy has not been
proven, intratympanic steroids are being increasingly used as a
therapeutic option for SSNHL worldwide. The published data
shows that intratympanic steroids in SSNHL are mostly used as
salvage treatment after systemic steroids (7). However, the effi-
cacy of ITD for severe to profound SSNHL has not yet been
determined.
This study evaluated the effect of using ITD as a salvage treat-
ment for severe to profound SSNHL.
MATERIALS AND METHODS
We reviewed the medical records of all patients with SSNHL and
who were seen from January 2007 and December 2009 at our
hospital. This study was approved by the Institutional Review
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The patients with unilateral SSNHL with an average hearing
loss greater than 70 dB across four frequencies (500, 1,000,
2,000, and 3,000 Hz), were included in this study. The patients
were divided into two groups: the severe hearing loss group with
a loss between 70 and 90 dB (25 patients) and the profound
hearing loss group with a loss greater than 90 dB (22 patients).
All the patients were hospitalized and they were all were
treated with intravenous dexamethasone (10 mg/d for 5 days,
7.5 mg/d for 2 days) for seven days and then with oral steroids
(prednisolone) for 3 days in tapered doses after the patients were
discharged from the hospital. We performed audiometry 2 weeks
after the primary systemic steroid treatment. If the patient did
not show a complete or partial recovery, then we considered
them for ITD as salvage treatment. The intratympanic steroid
injection was repeated for a total of six injections over 2 weeks.
Topical anesthesia was applied with 10% lidocaine spray from
a spray pump. With the patient in the supine position and with
the head tilted 45 to the opposite side, a 25-gauge spinal nee-
dle was passed through the anterosuperior portion of the tym-
panic membrane. Approximately 0.3 to 0.4 mL of dexametha-
sone (5 mg/mL) was instilled. 
Successful recovery at 1 month after ITD therapy was defined
as complete or partial recovery using Siegel’s criteria. “complete
recovery” was defined as final hearing better than 25 dB and
“partial recovery” as a hearing gain exceeding 15 dB and the
final hearing was between 25 and 45 dB.
Statistical tests were performed using Fischer’s exact test for
categorical variables and Student’s t-test for continuous variables
(SPSS ver. 14.0, SPSS Inc., Chicago, IL, USA).
RESULTS
The demographics and audiological data of the patients are
summarized in Table 1. The patients in the severe SSNHL group
showed significant overall improvement compared with that of
the profound SSNHL group (Fig. 1).
The early recovery rate 2 weeks after the initial systemic treat-
ment was 36% (9/25) in the severe SSNHL group and 18.1%
(4/22) in the profound SSNHL group (Fig. 2). By contrast, the
recovery rate of ITD as a salvage treatment was 37.5% (6/16)
in the severe SSNHL group and 5.5% (1/18) in the profound
SSNHL group (Fig. 3). The total recovery rate of ITD as a sal-
Severe group Profound group
P-value
(n=25) (n=22)
Table 1. Demographic and audiologic features of the patients
Age (years) 46.6±16.7 47.1±15.6 0.917
Gender (male:female) 17:8 15:7 0.989
Dizziness (%) 7 (28) 5 (22.7) 0.747
Duration (days) 2.9±1.8 2.5±1.8 0.49
Hearing level (dB) 78.2 108.5
Fig. 1. Comparison of the overall recovery rate between the severe
and profound sudden sensorineural hearing loss groups. *P<0.05.
22.7
60
(%) 100
90
80
70
60
50
40
30
20
10
0
Severe Profound
*
Fig. 2. Comparison of the early recovery rate 2 weeks after systemic
steroids between the severe and profound sudden sensorineural
hearing loss groups. P=0.207.
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Fig. 3. Comparison of the recovery rate after administering intratym-
panic dexamethasone between the severe and profound sudden
sensorineural hearing loss groups. *P<0.05.
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was 20.6% (7/34).
Of the patients in the severe SSNHL group who recovered
after ITD, four showed complete recovery and two patients
showed partial recovery. The only patient who recovered after
ITD in the profound SSNHL group showed partial recovery. 
DISCUSSION
This study examined the efficacy of ITD as a salvage treatment
for severe to profound SSNHL. SSNHL is a very frightening
and incapacitating event and it severely impairs the patient’s
quality of life and ability to interact socially. Patients with severe
to profound SSNHL have difficulty with hearing rehabilitation
such as hearing aids if their hearing recovery is poor.
The use of intratympanic steroids (ITS) has evolved into three
main protocols for the treatment of SSNHL. In the first, ITS are
used as adjuvant treatment and they are given concomitantly
with systemic steroids for SSNHL. Battaglia et al. (8) reported
that combination therapy (ITD+systemic steroid) had a greater
likelihood of inducing hearing recovery than systemic steroid
alone. Ahn et al. (9) reported that the addition of ITD to systemic
steroids did not result in a significant improvement in the treat-
ment of SSNHL; however, these findings are in contrast to the
results of Battaglia et al. (8). We did not choose this modality
for treating SSNHL because even the patients who show good
recovery with systemic steroid alone would be given unneces-
sary ITD.
In the second modality, ITS are used as the initial or primary
treatment for SSNHL without systemic steroid. The primary
reason is to avoid systemic side effects, such as peptic ulcers and
osteonecrosis. Kara et al. (10) reported that ITD alone achieved
better hearing results than systemic steroids, while Hong et al.
(11) reported that the group given ITD as primary therapy
showed no difference in the hearing recovery, as compared
with the systemic steroid group, although the threshold of the
improvement was greater in the systemic steroid group than in
the ITD group at high frequencies (4 and 8 kHz). However, only
two papers have studied the effect of intratympanic steroids as
primary therapy without systemic steroids. More studies are
needed to clarify the effect of this modality. In addition, the side
effects of systemic steroids in patients with SSNHL are very
rare because side effects are usually associated with long-term
therapy and ITD has potential negative outcomes such as pain,
tympanic membrane perforation, otorrhea and vertigo. On the
other hand, this modality has an advantage for patients with
diabetes because systemic steroids in patients with diabetes require
paying very close attention to the glycemic control. Han et al.
(12) reported that ITD is as effective as systemic steroid treat-
ment for SSNHL patients with diabetes.
In the third modality, ITS are used as salvage therapy after
the failure of systemic steroids for SSNHL. The majority of stud-
ies in the literature concerning the use of ITS in the treatment
of SSNHL has reported on this as salvage therapy. The percent-
age of successful treatment after ITD has ranged from 12% to
100% because each study used different criteria to assess improve-
ment (10, 13). Many authors defined successful treatment as a
10 or 15 dB improvement. A few studies defined it as a 20 or 30
dB improvement on PTA (13, 14). In comparison, we defined
“successful recovery” as complete and partial recovery using
Sigel’s criteria, with excluding slight recovery. If we included
mild improvement, such as a 10 or 15 dB gain, in successful recov-
ery, then the recovery rate would be higher. For cases of severe
to profound hearing loss, we believed that a mild improvement
would not satisfy the patients.
Our treatment protocol consists of systemic steroids and then
ITD as salvage treatment. First, we performed audiometry 2 weeks
after the primary systemic steroid treatment. If the patient did
not show a complete or partial recovery, then we considered
them for ITD as salvage treatment. When to start the salvage
treatment is controversial. Moon et al. (15) reported that the
prognosis of SSNHL could be predicted approximately 2 weeks
after the start of treatment because the time of commencement
shows a plateau after 2 weeks in the cases that improved.
We showed that the efficacy of ITD significantly differed
between the severe and profound SSNHL groups. It has been
previously demonstrated that systemic steroids in patients with
profound SSNHL result in an extremely poor prognosis. Our
study showed that ITD as salvage treatment for patients with
profound SSNHL also has a very poor prognosis.
Our comparative study does not support the efficacy of ITD
as a salvage treatment for patients with profound SSNHL as
compared with that for severe SSNHL. We recommend that
patients with profound SSNHL be informed of the low efficacy
of ITD as a salvage treatment.
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